Urovant Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Urovant Sciences, Inc.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
- Specialty Pharmaceuticals